HMGA2 Expression in Renal Carcinoma and its Clinical Significance

• Published in: Journal of medical biochemistry Vol. 34; no. 3; pp. 338 - 343
• Main Authors: Liu, Ying, Fu, Qi-Zhong, Pu, Lin, Meng, Qing-Guo, Liu, Xian-Feng, Dong, Sheng-Fang, Yang, Jian-Xun, Lv, Guang-Yao
• Format: Journal Article
• Language: English
• Published: Serbia Society of Medical Biochemists of Serbia 01.07.2015; Society of Medical Biochemists of Serbia, Belgrade
• Subjects: high mobility group a2; immunohistochemistry; Original Paper; renal carcinoma; rt-pcr; high mobility group A2; renal carcinoma; immunohistochemistry; RT-PCR
• ISSN: 1452-8258; 1452-8266
• DOI: 10.2478/jomb-2014-0036

The objective of this study is to detect HMGA2 expression in renal carcinoma to explore its relationship with clinicopathology and its significance in prognosis. Expressions of HMGA2 mRNA and protein were detected in 50 renal carcinoma specimens, 50 corresponding adjacent normal kidney tissue samples and 40 renal benign tumour specimens via reverse transcription polymerase chain reaction and immunohistochemical assay. Expression analysis was performed along with clinical data analysis. The relative expression levels of HMGA2 mRNA in renal carcinoma, renal benign tumour tissues and adjacent normal renal tissues were 0.84±0.23, 0.19±0.06 and 0.08±0.04, respectively. HMGA2 protein positive rates were 68.0%, 7.5% and 2.0%, with a significant difference ( <0.05). HMGA2 expression was not significantly correlated with gender, age, tumour size and histological type ( >0.05), but was significantly correlated with TNM stages and lymph node metastasis ( <0.05). The expressions of HMGA2 gene and protein in renal carcinoma were closely correlated with tumour formation, progression and metastasis. HMGA2 may become a powerful new pathological marker and prognostic factor for renal carcinoma.